$中慧生物-B(02_老虎社区_美港股上老虎

$中慧生物-B(02627)$ 公司自主研发的国内首款全人群三价流感病毒亚单位疫苗（慧尔康欣3）成功中标山西省非免疫规划疫苗增补采购项目，标志着该重磅新品从获批迅速走向市场销售，开始贡献实际收入

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":540836879630560,"tweetId":"540836879630560","gmtCreate":1773058308418,"gmtModify":1773058310792,"author":{"id":4203843771083212,"idStr":"4203843771083212","authorId":4203843771083212,"authorIdStr":"4203843771083212","name":"乐山大佛笑哈哈","avatar":"https://community-static.tradeup.com/news/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":1,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 公司自主研发的国内首款全人群三价流感病毒亚单位疫苗（慧尔康欣3）成功中标山西省非免疫规划疫苗增补采购项目，标志着该重磅新品从获批迅速走向市场销售，开始贡献实际收入</p></body></html>","htmlText":"<html><head></head><body><p><a href=\"https://laohu8.com/S/02627\">$中慧生物-B(02627)$ </a> 公司自主研发的国内首款全人群三价流感病毒亚单位疫苗（慧尔康欣3）成功中标山西省非免疫规划疫苗增补采购项目，标志着该重磅新品从获批迅速走向市场销售，开始贡献实际收入</p></body></html>","text":"$中慧生物-B(02627)$ 公司自主研发的国内首款全人群三价流感病毒亚单位疫苗（慧尔康欣3）成功中标山西省非免疫规划疫苗增补采购项目，标志着该重磅新品从获批迅速走向市场销售，开始贡献实际收入","highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/540836879630560","repostId":0,"isVote":1,"tweetType":1,"viewCount":103,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":["02627"],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":176,"optionInvolvedFlag":false,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}